Dengler Jana, Radisic Milica
Institute of Biomaterials & Biomedical Engineering, Department of Chemical Engineering & Applied Chemistry, Heart & Stroke Richard/Lewar Centre of Excellence, University of Toronto, 164 College Street, Room 407, Toronto, Ontario, CA M5S3G9, Canada.
Future Cardiol. 2007 Jul;3(4):425-34. doi: 10.2217/14796678.3.4.425.
Cardiac tissue engineering is an emerging field that aims to enhance cardiac function in patients with heart disease or congenital malformations, by providing suitable implantable replacement tissues. Various groups have developed methods of cultivating contractile 3D cardiac grafts that display functional and morphological properties of native myocardium, integrate into native tissue and provide improvement in cardiac function upon grafting onto infarcted hearts. However, several critical goals must be met before this therapy can be implemented clinically: the identification and harvesting of an appropriate human cell source, the cultivation of relatively thick ( approximately 1 cm) constructs, and the in vitro and/or in vivo vascularization of these constructs. Advances in enabling bioreactor technologies and the identification of key parameters governing the differentiation of cardiac cells will be crucial to advancement in this field.
心脏组织工程是一个新兴领域，旨在通过提供合适的可植入替代组织，增强患有心脏病或先天性畸形患者的心脏功能。多个研究团队已开发出培养收缩性三维心脏移植物的方法，这些移植物展现出天然心肌的功能和形态特性，能整合到天然组织中，并在移植到梗死心脏后改善心脏功能。然而，在这种疗法能够临床应用之前，必须实现几个关键目标：确定并获取合适的人类细胞来源、培养相对较厚（约1厘米）的构建体，以及使这些构建体在体外和/或体内实现血管化。推动生物反应器技术的进步以及确定控制心脏细胞分化的关键参数，对于该领域的进展至关重要。
